ADIAL PHARMACEUTICALS, INC. 8-K

What Happened

• Adial Pharmaceuticals, Inc. (ADIL) filed an 8-K on Jan 6, 2026 announcing that James W. Newman, Jr. resigned from the Company's Board of Directors effective Jan 5, 2025.
• Mr. Newman served as a non-employee director and was a member of the Board’s Audit Committee and Compensation Committee. The filing states he did not report any disagreement with the Company regarding its operations, policies or practices.

Key Details

• Resignation effective date: January 5, 2025.
• 8-K filing date (reported): January 6, 2026.
• Roles held: non-employee director; member of Audit Committee and Compensation Committee.
• Filing notes: no disagreements with the Company were reported; no replacement director was named in the filing.

Why It Matters

• For investors, the departure of an Audit and Compensation Committee member can affect board oversight of financial reporting and executive pay until committees are reconstituted.
• Because Mr. Newman was a non-executive director and the filing discloses no disagreements, the company characterizes this as a routine board change rather than a public dispute.
• Watch future filings and proxy materials for announcements about a replacement director or changes to committee membership.